Bioptik Technology (4161) — Cash Flow Reinvestment Rate
Bioptik Technology (4161) has a Cash Flow Reinvestment Rate of 0.09x as of December 2025, reinvesting NT$4.94 Million (capex NT$4.94 Million ) from operating cash flow of NT$53.21 Million. See 4161 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Bioptik Technology Cash Flow Reinvestment Rate (2017–2025)
Historical reinvestment intensity for Bioptik Technology across 8 annual periods. For the full cash flow conversion analysis, see 4161 cash flow conversion.
Annual Cash Flow Reinvestment Rate for Bioptik Technology (2017–2025)
Year-by-year capital reinvestment analysis for Bioptik Technology. See Bioptik Technology leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.65x | NT$39.23 Million | NT$59.99 Million | NT$22.80 Million | ▲ +481.8% |
| 2024 | 0.11x | NT$17.85 Million | NT$158.82 Million | NT$15.51 Million | ▼ -61.1% |
| 2023 | 0.29x | NT$59.58 Million | NT$205.95 Million | NT$31.04 Million | ▼ -92.8% |
| 2022 | 4.02x | NT$221.24 Million | NT$55.06 Million | NT$17.08 Million | ▼ -80.0% |
| 2020 | 20.13x | NT$132.29 Million | NT$6.57 Million | NT$13.18 Million | ▲ +214.2% |
| 2019 | 6.40x | NT$262.81 Million | NT$41.03 Million | NT$27.42 Million | ▲ +77.1% |
| 2018 | 3.62x | NT$151.22 Million | NT$41.83 Million | NT$50.96 Million | ▼ -78.0% |
| 2017 | 16.46x | NT$181.43 Million | NT$11.02 Million | NT$62.72 Million | — |